A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- Sponsors Janssen-Cilag
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.